G12D mutation in the KRAS gene, a lung adenocarcinoma gene, may be directly related to recurrence, a study has shown. The presence of KRAS mutations in non-small cell lung cancer is associated with shortened survival and time to recurrence.
The main purpose of detecting KRAS gene G12D mutation or other gene mutations in lung adenocarcinoma is to guide the treatment of clinically targeted drugs, and to select different targeted drugs for treatment according to different gene mutations.
All malignant tumors have the risk of recurrence. It is difficult to kill all the cancer cells completely by radiotherapy, chemotherapy and other treatments, and if the residual cancer cells are not killed by the body’s own immune system, there is a possibility of recurrence. Surgical resection is the main treatment for lung cancer and the only possible cure for lung cancer at present.
Lung adenocarcinoma should go to the hospital in time and be treated under doctor’s guidance, and follow the doctor’s instructions for regular follow-up.